Treatment of chronic hepatitis C virus infection;Tratamiento de la infección crónica por el VHC

Anales del Sistema Sanitario de Navarra

Volumn 27, Issue SUPPL. 2, 2004, Pages 81-90

  Elizalde, I ^a   Inarrairaegui M ^a   Rodriguez Gutierrez C ^b   Zozaya, J M ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b HOSPITAL GARCÍA ORCOYEN   (Spain)

Author keywords

Chronic infection; Hepatitis C virus; Pegylated interferon; Rivabirin

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CHRONIC HEPATITIS; DRUG MEGADOSE; ECONOMIC ASPECT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER TOXICITY; POLYMERASE CHAIN REACTION; REVIEW;

DECISION TREES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; RETREATMENT;

EID: 4544274329     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. KEATING GM, CURRAN MP. Peginterferon-a- 2 a (40 kD) plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 701-730.
2. OLASO PEIRÓ V, CóRDOVA CORTIJO J, PRIETO CASTILLO M. Tratamiento de la hepatitis crónica C. Rev Esp Enf Digest 1997; 89: 621-637.
3. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-june 10-12, 2002. Hepatology 2002; 36 (Suppl 1): S3-S15.
4. ALBERTI L. BENGEGNU̇. Management of hepatitis C. J Hepatol 2003; 38: S104-Sl18.
5. FRIED MW, SHIFFMAN ML, REDDY R, SMIH C, MARINOS G, GONCALES F et al. Peginterferón alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
6. MANNS MP, McHUTCHISON JG, GOROON SC, RUSTGI VK, SHIFFMAN M, REINDOLLAR R et al. Peginterferon alfa2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 338: 958-965.
7. Conférence de consensus traitement de l'hepatite C. París 27-28 février 2002.
8. EASL International consensus conference on hepatitis C. París, 26-28 February 1999. Consensus Statement. J Hepatol 1999; 30: 956-961.
9. SHIFFMAN ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36 (Suppl 1): S128-134.
10. HADZIYANNIS SJ, SETTE H, MORGAN TR, BALAN V, DIAGO M, MARCELLIN P et al. Peginterferon alfha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
11. BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
12. BACON BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. NIH Consensus Development Conference Statement: Management of Hepatitis C 2002. Hepatology 2002; 36 (Suppl 1): S179-184.
13. ZEUDEM S, DIAGO M, GANE E, REDDY R, POCKROS P, FARCI P et al. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 KD) (PEGASYS®) and ribavirin (COPEGUS®). AASLD Annual Meeting and postgraduate Course, Boston
14. SHIFFMAN M, HALT-C Trial Investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead against cirrhosis (HALT-C) trial. Hepatology 2002; 36: 295 A.
15. HEATHCOTE EJ. Treatment considerations in patients with hepatitis C and cirrhosis. J Clin Gastroenterol 2003; 37: 395-398.
16. WRIGHT TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36 (Suppl 1): S185-194.
17. JACOBSON IM, RUSSO MW, BROWN RS, LEBOVICS E, MIN A, ESPOSITO S et al. Pegylated interferon alfa-2b in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Gastroenteroloy 2002; 36 (Supp 1): A626.
18. MORENO L, QUEREDA C, MORENO A, PEREZ-ELÍAS MJ, ANTELA A, CASADO JL et al. Pegylated interferon a2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.
19. BRÁU N. Update on chronic hepatitis C in HIV/HCV - coinfected patientes: viral interaccions and therapy. AIDS 2003; 17: 2279-2290
20. SÁNCHEZ-QUIJANO A, LEAL M, LISSEN E. Hepatitis crónica por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana. Gastroenterol Hepatol 2002; 25: 423-431.
21. LAFEUILLADE A, HITTINGER G, CHADAPAUD S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
22. MCHUTCHISON JG, PATEL K. Future therapy of hepatitis C. Hepatology 2002; 36 (Suppl 1): S245-252.